Correlation Between Relmada Therapeutics and Cue Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Relmada Therapeutics and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Relmada Therapeutics and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Relmada Therapeutics and Cue Biopharma, you can compare the effects of market volatilities on Relmada Therapeutics and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Relmada Therapeutics with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Relmada Therapeutics and Cue Biopharma.

Diversification Opportunities for Relmada Therapeutics and Cue Biopharma

-0.57
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Relmada and Cue is -0.57. Overlapping area represents the amount of risk that can be diversified away by holding Relmada Therapeutics and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Relmada Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Relmada Therapeutics are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Relmada Therapeutics i.e., Relmada Therapeutics and Cue Biopharma go up and down completely randomly.

Pair Corralation between Relmada Therapeutics and Cue Biopharma

Given the investment horizon of 90 days Relmada Therapeutics is expected to generate 2.17 times more return on investment than Cue Biopharma. However, Relmada Therapeutics is 2.17 times more volatile than Cue Biopharma. It trades about 0.37 of its potential returns per unit of risk. Cue Biopharma is currently generating about -0.23 per unit of risk. If you would invest  207.00  in Relmada Therapeutics on August 16, 2025 and sell it today you would earn a total of  188.00  from holding Relmada Therapeutics or generate 90.82% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Relmada Therapeutics  vs.  Cue Biopharma

 Performance 
       Timeline  
Relmada Therapeutics 

Risk-Adjusted Performance

Strong

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Relmada Therapeutics are ranked lower than 26 (%) of all global equities and portfolios over the last 90 days. In spite of rather abnormal primary indicators, Relmada Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.
Cue Biopharma 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Cue Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Relmada Therapeutics and Cue Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Relmada Therapeutics and Cue Biopharma

The main advantage of trading using opposite Relmada Therapeutics and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Relmada Therapeutics position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.
The idea behind Relmada Therapeutics and Cue Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Complementary Tools

CEOs Directory
Screen CEOs from public companies around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments